Revenue (Tables)

12 Months Ended

Dec. 31, 2024

Revenue [abstract]

Schedule of Revenue Recognized in Consolidated Statement of Profit or Loss

Revenue has been recognized in the consolidated statements of profit or loss with the following amounts:

	2024		2023		2022
	(EUR’000)
Revenue
Commercial products		225,728		178,663		35,659
Rendering of services		11,794		21,659		4,434
Clinical supply		3,776		319		8,534
Licenses		122,343		66,077		2,547
Total revenue		363,641		266,718		51,174
Attributable to
Commercial customers		225,728		178,663		35,659
Collaboration partners and license agreements		137,913		88,055		15,515
Total revenue		363,641		266,718		51,174
Specified by timing of recognition
Recognized over time		11,794		21,659		4,434
Recognized at a point in time		351,847		245,059		46,740
Total revenue		363,641		266,718		51,174
Specified per geographical area
Europe (1)		123,336		869		552
North America		233,220		191,677		44,156
Rest of world		7,085		74,172		6,466
Total revenue		363,641		266,718		51,174

(1)For the year ended December 31, 2024, Denmark, the country of domicile, contributed with €95.4 million of revenue.

Schedule of Revenue Attributable to Commercial Customers by Product

Revenue attributable to commercial customers by product were as follows:

	2024	2023	2022
	(EUR’000)
Revenue from commercial products
SKYTROFA®	197,001	178,663	35,659
YORVIPATH®	28,727	—	—
Total revenue from commercial products	225,728	178,663	35,659